Harmony Biosciences Holdings, Inc.
HRMY
$35.54
$1.143.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 744.85M | 714.73M | 681.88M | 656.11M | 617.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 744.85M | 714.73M | 681.88M | 656.11M | 617.51M |
| Cost of Revenue | 161.33M | 156.82M | 145.56M | 135.08M | 127.94M |
| Gross Profit | 583.53M | 557.92M | 536.32M | 521.03M | 489.57M |
| SG&A Expenses | 230.31M | 221.27M | 219.56M | 209.36M | 200.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 549.81M | 523.91M | 506.58M | 478.02M | 413.87M |
| Operating Income | 195.04M | 190.83M | 175.30M | 178.09M | 203.64M |
| Income Before Tax | 197.20M | 191.80M | 175.34M | 165.00M | 187.40M |
| Income Tax Expenses | 44.48M | 46.31M | 52.71M | 50.01M | 49.70M |
| Earnings from Continuing Operations | 152.72 | 145.49 | 122.63 | 114.99 | 137.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 152.72M | 145.49M | 122.63M | 114.99M | 137.70M |
| EBIT | 195.04M | 190.83M | 175.30M | 178.09M | 203.64M |
| EBITDA | 218.99M | 214.94M | 199.56M | 202.50M | 228.06M |
| EPS Basic | 2.68 | 2.56 | 2.15 | 1.98 | 2.35 |
| Normalized Basic EPS | 2.16 | 2.11 | 1.92 | 1.88 | 2.10 |
| EPS Diluted | 2.62 | 2.51 | 2.11 | 1.95 | 2.31 |
| Normalized Diluted EPS | 2.12 | 2.07 | 1.89 | 1.85 | 2.07 |
| Average Basic Shares Outstanding | 228.08M | 227.54M | 228.76M | 231.76M | 234.93M |
| Average Diluted Shares Outstanding | 232.39M | 231.46M | 232.10M | 234.67M | 237.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |